Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in TWN: A prospective observational study

International Journal of Dermatology

Volumn 54, Issue 5, 2015, Pages 529-536

  Tsai, Tsen Fang ^a   Yao, Chien An ^a   Yu, Hsin Su ^b   Lan, Cheng Che ^b   Chao, Sheau Chiou ^c   Yang, Jen Hung ^d,e   Yang, Kuo Chia ^f   Chen, Ching Yu ^a   White, Ron R ^g   Psaradellis, Eliofotisti ^h   Rampakakis, Emmanouil ^h,i   Kawai, Kosuke ^j   Acosta, Camilo J ^g   Sampalis, John S ^h,i  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g MERCK RESEARCH LABORATORIES   (United States)

^h JSS Medical Research   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j TEMPLE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; TOPICAL AGENT; VALACICLOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DERMATOME; DETERIORATION; DISEASE DURATION; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH STATUS; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INITIAL ZOSTER IMPACT QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; PAIN SEVERITY; PHYSICIAN; PHYSIOTHERAPIST; POSTHERPETIC NEURALGIA; PROSPECTIVE STUDY; QUALITY OF LIFE; RASH; TAIWAN; ZOSTER BRIEF PAIN INVENTORY; COMPLICATION; NEURALGIA, POSTHERPETIC; PATIENT ATTITUDE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME;

FEMALE; HERPES ZOSTER; HUMANS; MALE; NEURALGIA, POSTHERPETIC; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TAIWAN; TIME FACTORS;

EID: 84928325439     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12484     Document Type: Article

References (45)

1. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: 340-346.
2. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003; 70 (Suppl. 1): S9-S14.
3. de Melker MH, Berbers G, Hahne S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24: 3946-3952.
4. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-753.
5. Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133: 245-253.
6. Lin YH, Huang LM, Chang IS, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine TWN. Vaccine 2010; 28: 1217-1220.
7. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.
8. Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008; 9 (1 Suppl. 1): S3-S9.
9. Volpi A, Gross G, Hercogova J, et al. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005; 6: 317-325.
10. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197 (Suppl. 2): S207-S215.
11. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19: 471-475.
12. De Moaragas JM, Kierland RR. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193-196.
13. Hope Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25: 571-575.
14. Watson CP. Postherpetic neuralgia. Neurol Clin 1989; 7: 231-248.
15. Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998; 17: 931-933.
16. Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008; 9 (1 Suppl. 1): S37-S44.
17. Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176: 1496-1500.
18. Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be managed? Herpes 2007; 14 (Suppl. 2): 30-34.
19. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47.
20. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32-42.
21. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349.
22. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145: 317-325.
23. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39: 342-348.
24. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6: 356-363.
25. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18: 350-354.
26. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007; 23: 490-496.
27. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106: 337-345.
28. Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010; 26: 656-666.
29. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004; 5: 344-356.
30. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008; 197(Suppl. 2): S228-S236.
31. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2: 169-180.
32. Zelman DC, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005; 115: 29-36.
33. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-1532.
34. Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain 2011; 15: 1100-1106.
35. Bouhassira D, Chassany O, Gaillat J, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012; 153: 342-349.
36. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33: 62-69.
37. Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182: 1731-1736.
38. van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35: 132-137.
39. Aunhachoke K, Bussaratid V, Chirachanakul P, et al. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol 2011; 50: 428-435.
40. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss 2012; 20: 441-451.
41. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010; 8: 37.
42. Lydick E, Epstein RS, Himmelberger D, et al. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45 (12 Suppl. 8): S52-S53.
43. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in TWN: a national study 2000 to 2006. Acta Derm Venereol 2006; 89: 612-616.
44. Su H-Y, Lin Y-J, Chen H-C. Herpes zoster - Clinical analysis of 780 inpatients. Dermatol Sinica 1991; 9: 183-192.
45. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-1551.